Loading
RP
Remus Pharmaceuticals Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Alkaben Dipakkumar Shah, was filed 12 Jan 2026.
Remus Pharmaceuticals Limited: what insiders have been doing
Remus Pharmaceuticals Limited, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEBI (PIT + SAST). Over the twelve months to 20 October 2026, 5 filings were filed, from 5 insiders.
No insider sold shares on the market over the period. Instead, the filings list 5 purchases totalling €36k, made by 5 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 5 major shareholders. Biggest ticket of the year: €17k, bought by Alkaben Dipakkumar Shah and made public on 12 January 2026.
In the case of 4 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 12 January 2026, 285 days ago. The median gap between a trade and its publication by SEBI (PIT + SAST) is 4 days. That lag is the time during which only the insider knows about the trade.
With 5 filings in twelve months, the company is more active than the median of 4 filings across the 1,890 companies we follow on the same exchange. The full history, which starts in 2023, counts 211 purchases against 3 sales.
In the same sector, recent insider purchases at Vivos Inc and Anixa Biosciences Inc also feature in our signals. This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
Insider Decl.
214
Thresholds
n/a
Buy Volume
€3M
211 ops. · all time
Sell Volume
€33,430
3 ops. · all time
Who traded when
BuySaleVinodkumar Gandalal Shah5 buys1 sale
Renosen Pharmaceuticals Private Limited4 buys
Dhruvalben V Shah2 buys
Alkaben Dipakkumar Shah1 buy
Arpit Deepakkumar Shah1 buy
Roma Vinodbhai Shah1 buy
Since the insiders bought
- -9.8%Entry ₹706.00 · Close at T+90 ₹636.85
- -11.5%Entry ₹709.55 · Close at T+90 ₹627.90
- -14.4%Entry ₹734.00 · Close at T+90 ₹628.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,372 of 26,250 companies
43.7
score / 100
Value39
Quality48
FCF yld0.3%
Earn yld3.2%
EV/EBITDA18.7x
ROE·
Gross mgn13%
Net mgn4.3%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹984.50
Income statement
Revenue₹8.5B
Gross profit₹1.1B13% margin
EBITDA₹633.9M7% margin
Net income₹369.9M4.3% margin
Balance sheet & cash
Market cap₹11.6B
Total debt₹270.7M
Free Cash Flow₹35.9M
Last declaration on 12 January 2026
Declarations214 total
2,600 shares@ ₹708.65100.0% of flowEquity SharesSEBI:f9eec4f56a6bd0156c33c8d538907c7efef2196c
Canonical exit: 2 Apr 2026 (T+90)
1,200 shares@ ₹737.201.3% of flowEquity SharesSEBI:1ed48e6902256a8acb5babae583d722504dfbb7f
Canonical exit: 19 Mar 2026 (T+90)
500 shares@ ₹751.580.4% of flowEquity SharesSEBI:8536e571a6c83a6c14cb994159fc90b28cebf536
Canonical exit: 19 Mar 2026 (T+90)
500 shares@ ₹721.009.7% of flowEquity SharesSEBI:026fef6719e40deb77212a329355812dc464af21
Canonical exit: 11 Mar 2026 (T+90)
500 shares@ ₹723.3733.7% of flowEquity SharesSEBI:7ee7397f590cec5f66709bcfe02bc9eac2311ba9
Canonical exit: 10 Mar 2026 (T+90)
200 shares@ ₹730.000.1% of flowEquity SharesSEBI:255ac3578df38b9d99108bb545ad7b1d3c3105d8
Canonical exit: 29 Dec 2025 (T+90)
3,000 shares@ ₹800.004.8% of flowEquity SharesSEBI:a844cfbefac12ef8a32eb347c489d6e4d79a2711
Canonical exit: 21 Dec 2025 (T+90)
200 shares@ ₹854.7254.7% of flowEquity SharesSEBI:39fe14adf6b4d9ff5c8eeabd2d3e3c565e432eab
Canonical exit: 5 Nov 2025 (T+90)
400 shares@ ₹1,984.120.9% of flowEquity SharesSEBI:f695d17363a1c38e2e5b31c218c6a64cab453828
Canonical exit: 4 May 2025 (T+90)
200 shares@ ₹2,027.330.5% of flowEquity SharesSEBI:a0f7b85c06a2054c90323f30eb97f185a4e06962
Canonical exit: 4 May 2025 (T+90)
50 shares@ ₹2,385.0013.1% of flowEquity SharesSEBI:4fc18aa0321c694da71d079c45eac39716519bbb
Canonical exit: 6 Apr 2025 (T+90)
50 shares@ ₹2,403.5613.1% of flowEquity SharesSEBI:57109d788856327ca4cb135ce23d38d2de9d583e
Canonical exit: 30 Mar 2025 (T+90)
50 shares@ ₹2,525.0013.9% of flowEquity SharesSEBI:f27a65dfe9fcc09fe469b100a7071d04383ec149
50 shares@ ₹2,425.0013.3% of flowEquity SharesSEBI:57d2854ce7d7fa8f0598f290ddddca139d458ad8
Canonical exit: 6 Apr 2025 (T+90)
50 shares@ ₹2,345.0012.8% of flowEquity SharesSEBI:6409aec7439c636afe5b5d2aa1eda450278f3e07
Canonical exit: 7 Apr 2025 (T+90)
100 shares@ ₹2,688.950.4% of flowEquity SharesSEBI:3fc3d7cdaf5c391116f88032770954f41b5ebc60
Canonical exit: 23 Dec 2024 (T+90)
400 shares@ ₹2,689.001.8% of flowEquity SharesSEBI:c1de8f1f1850ace35d1e9d8461198bf8dca172b0
Canonical exit: 23 Dec 2024 (T+90)
500 shares@ ₹2,689.002.2% of flowEquity SharesSEBI:252b1906a72072fe6ae413f5f5d1b5a6599e48a2
Canonical exit: 23 Dec 2024 (T+90)
300 shares@ ₹2,371.600.8% of flowEquity SharesSEBI:497032be8b5382fde6d8f7e61e504d6f6e9291a0
Canonical exit: 17 Dec 2024 (T+90)
100 shares@ ₹2,379.000.3% of flowEquity SharesSEBI:3a2659fb138bc1e53d9fa32ccc6b3649120ab801
Canonical exit: 17 Dec 2024 (T+90)
100 shares@ ₹2,393.000.3% of flowEquity SharesSEBI:12caf91c095ea315c4fd9e432f0c8cf8cf95caad
Canonical exit: 17 Dec 2024 (T+90)
100 shares@ ₹2,369.000.3% of flowEquity SharesSEBI:6f162052571e4876a29e2cf72e55c43a3e7bd6fa
Canonical exit: 17 Dec 2024 (T+90)
300 shares@ ₹2,405.000.8% of flowEquity SharesSEBI:9a0852ad46f853b3917002f2a1b332ee8b509bef
Canonical exit: 17 Dec 2024 (T+90)
2,000 shares@ ₹2,276.405.3% of flowEquity SharesSEBI:51cb63b91d267ab74d4d053e4b8370023a67049e
Canonical exit: 14 Nov 2024 (T+90)
1,000 shares@ ₹2,037.492.4% of flowEquity SharesSEBI:71dcf15c795b1c88695bc266e2ca6628332a21ac
Canonical exit: 3 Nov 2024 (T+90)
25 of 214 declarations
About Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is a company focused on developing innovative drugs in the healthcare and pharmaceutical sector. It is listed on the XBOM.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
